PT-141 / Bremelanotide

Overview

PT-141 is the only FDA-approved drug that works on sexual desire by targeting the brain rather than the genitals — and that distinction matters more than it might sound. Approved under the brand name Vyleesi in 2019, it's a synthetic melanocortin receptor agonist used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women, and it's prescribed off-label for erectile dysfunction (ED) in men.[1]

The compound is a 7-amino acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Its generic name is bremelanotide. Palatin Technologies developed it originally as a nasal spray for ED before pivoting to subcutaneous injection and the HSDD indication.[2]

If you've tried PDE5 inhibitors like sildenafil or tadalafil and found they don't address the desire side of things — or if you're a woman with HSDD looking for an FDA-approved option — PT-141 is one of the very few compounds that has actually been through Phase 3 trials for this specific problem.[1]

Mechanism of Action

MC3R and MC4R agonism in the central nervous system

PT-141 is a synthetic analog of alpha-MSH, a naturally occurring neuropeptide. It binds to melanocortin receptors — specifically MC3R and MC4R — which are concentrated in the hypothalamus and other regions of the brain involved in sexual motivation and arousal.[3]

When those receptors are activated, they trigger downstream neural signaling that increases sexual desire and, in men, initiates the erectile response through central pathways. In rat studies, systemic PT-141 administration activated neurons in the hypothalamus (measured by c-Fos immunoreactivity), and those same hypothalamic neurons have direct neural connections to the corpus cavernosum — the erectile tissue of the penis.[3] That's the mechanistic link: brain activation → spinal cord signaling → genital response.

In women, the mechanism is analogous: central melanocortin activation appears to modulate the motivational component of sexual response. The Phase 3 trials for HSDD measured this not as a physiological endpoint but as patient-reported desire and distress — because that's what actually matters clinically.[1]

One important note: PT-141 does not affect sex hormone levels. It isn't a testosterone booster or an estrogen modulator. Its effect is purely through receptor-level signaling in the CNS.

What the Evidence Shows

Bremelanotide earned FDA approval in June 2019 based on two Phase 3 randomized, placebo-controlled trials in premenopausal women with acquired, generalized HSDD. AMAG Pharmaceuticals commercialized the drug in the US following an out-licensing agreement with Palatin Technologies.[1]

Both trials used patient-reported outcomes — specifically the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) — as primary endpoints. Women receiving bremelanotide 1.75 mg showed statistically significant improvements in sexual desire and reductions in distress compared to placebo.[1] The effect size was modest in absolute terms, but this is a condition with very few approved treatment options, and the on-demand dosing model is a practical advantage over daily medications.

The original development program for PT-141 focused on ED. In a Phase 2 study in men with psychogenic or organic ED — including a subset who had not responded to sildenafil — intranasal PT-141 produced significant improvements in erectile function compared to placebo.[3] By September 2003, Palatin had completed a Phase 2b trial in ED patients, with Phase 3 planning underway at the time of early publications.[2]

The ED development program ultimately did not advance to FDA approval under the current subcutaneous formulation, but the compound is used off-label for this indication through compounding pharmacies. The early-phase data is real; what's missing is a large Phase 3 RCT with the approved subcutaneous formulation in men.

PT-141's approval sits within a broader story about melanocortin receptors as therapeutic targets. The same year bremelanotide was approved for HSDD, another melanocortin-targeting drug was approved for erythropoietic protoporphyria. In 2020, setmelanotide — which targets the central melanocortin system — was approved for specific forms of genetic obesity.[4] This isn't a niche receptor system; it's an active area of drug development with multiple approved agents.

Side Effects
PT-141's side effect profile is well-characterized from Phase 3 trials. The good news: nothing here is severe for most people. The practical reality: nausea is common enough that it affects tolerability for some users.

What warrants a call to your provider: Chest pain, significant blood pressure elevation, or skin changes that progress or spread. Nausea and flushing that are severe enough to interfere with the intended effect of the drug — that's a tolerability conversation worth having, because dose timing and food intake can sometimes help.